SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming staking features and airdrop details. The community is actively discussing its consistent growth and dedication to long-term development, emphasizing its unique ecosystem. With a focus on community engagement and utility, Brokecoin aims to stand out in the meme coin space.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending as chatter focuses on Donald Trump's alleged connections to the Epstein case, with community members debating the validity and implications of related documents. Some are defending Trump, claiming the accusations are a hoax, while others criticize his associations and economic policies. The stock's performance and broader economic concerns under the current administration are also being discussed.

Memecoin on Injective taken over by the community.

Nonja

Nonja ($NONJA.X) is trending as community members express strong bullish sentiment, touting its potential for significant gains and highlighting its strong community. Community members emphasize $NONJA.X's solid presence within the Injective ($INJ.X) ecosystem, where it is the leading memecoin, noting its unique features and potential to outperform $INJ.X itself.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to takeover speculation fueled by a Betaville rumor mentioning a large American pharmaceutical company as a potential suitor. The community is discussing the validity of the rumor and comparing the stock's potential to previous significant runs in the biotech sector. Some investors hope for a buyout, while others prefer the company to remain independent for further growth.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

TROLL.X is trending following news of the Solana memecoin officially acquiring rights to the Trollface meme, leading to a surge in market cap. The community is discussing its potential for significant gains, drawing comparisons to other successful meme coins and highlighting its strong community. Some users are also pointing to $GASH.X as another coin with similar potential.

USELESS

$USELESS.X is gaining attention, with community members highlighting the potential for significant gains, referencing a possible 2000% move. Bullish sentiment seems to be driven by the coin's low market cap and community excitement around its potential, especially compared to other memecoins. Some users suggest that whales are accumulating $USELESS.X, anticipating a substantial pump.

Align Technology, Inc. is a medical device company, which engages in the design, manufacture, and market of orthodontics, restorative, and aesthetic dentistry products. It operates through the Clear Aligner and Systems and Services segments. The Clear Aligner segment consists of invisalign full, teen, and assist products, and Vivera retainers for treating malocclusion. The Systems and Services segment includes sales related to iTero intraoral scanning systems, which includes a single hardware platform and restorative or orthodontic software options, upgrades and leases of scanner systems, sales of pre-owned scanner systems, subscription software, disposables, pay per scan services, as well as exocad’s CAD/CAM software solutions that integrate workflows to dental labs and dental practices. The company was founded by Zia Chishti, Brian Freyburger, and Kelsey Wirth in March 1997 and is headquartered in Tempe, AZ.

Align Technology, Inc.

ALGN is trending as the community discusses recent price movement and future prospects, with some users drawing comparisons to SmileDirectClub's bankruptcy. Bullish investors point to share buybacks and insider buying as potential catalysts, while bears cite concerns about competition and market saturation. Discussions also include potential price targets and reactions to news from analysts.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAL is trending as the community discusses its potential in early cancer detection, highlighted by a recent article and a story about its life-saving importance. Some traders are taking profits, anticipating a retest, while others see long-term potential, particularly with possible FDA approval and broader access to its Galleri test. Volume and news catalysts are key talking points for future price movement.

WorldFinancial

World Liberty Financial ($WLFI.X) is trending as the community discusses its connection to Donald Trump and its potential in the stablecoin market. Conversations revolve around its USD1 stablecoin, comparisons to other cryptocurrencies, and predictions about its future value and adoption. Some traders are pointing to a large potential short squeeze.

Cyngn, Inc. engages in the development of autonomous driving software that can be deployed on multiple vehicle types in various environments. The company was founded by Kirt McMaster and Steve Kondik in 2013 and is headquartered in Mountain View, CA.

Cyngn Inc

CYN is trending due to a recent $300M mixed securities shelf offering, sparking concerns among investors about potential dilution and reverse stock splits. The community is actively discussing the implications of this offering, its effect on the stock's price, and the company's long-term financial stability. Despite a collaboration with NVIDIA, the stock's history of dilution and reverse splits remains a key point of discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low after the company announced a significant setback for its lead drug candidate, AK006.The biotech company revealed it would cease further clinical development of AK006 after its preclinical inhibitory effects failed to translate into clinical benefits for patients with chronic spontaneous urticaria (CSU).In the proof-of-concept trial, 34 adult patients with moderate-to-severe CSU refractory to antihistamines, with or without prior omalizumab exposure, were randomized 2:1 to receive AK006 or placebo.&nbsp;The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.&nbsp;The company will retain a small team of about 15 employees to explore strategic alternatives, ensure compliance, and oversee the wind-down of its phase 1 trial.Allakos ended the fourth quarter of 2024 with $81 million in cash and expects restructuring costs of $34–$38 million, primarily to be paid by mid-2025.&nbsp;The company estimates its cash reserves will decline to $35–$40 million by June 30, 2025.Following the announcement, several analysts adjusted their outlook on Allakos, according to The Fly.Piper Sandler downgraded the stock to ‘Neutral’ from ‘Overweight,’ slashing its price target to $0.30 from $7. The brokerage noted AK006 was Allakos’s sole asset, leaving the remaining valuation restricted to cash.JMP Securities downgraded Allakos to ‘Market Perform’ from ‘Outperform’.On Stocktwits, sentiment for Allakos shifted sharply to ‘bearish’ as disappointed retail investors voiced their concerns.&nbsp;<stembedurl>https://stocktwits.com/Majlo97/message/601635808</stembedurl><stembedurl>https://stocktwits.com/subieroo_wrx/message/601634053</stembedurl>Data showed declining interest in the stock, with a 4.6% drop in followers over the past year and a 44% reduction in message volume last week.<a href="https://stocktwits.com/symbol/ALLK">Allakos stock</a> has now lost 77% over the past 12 months, reflecting mounting challenges for the small-cap biotech as it faces an uncertain future.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

Equity

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024...

Leerink Partnrs Research Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK)

Allakos Inc. (NASDAQ:ALLK  Free Report)  Equities researchers at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Allakos in a research report issued to clients and...

Short Interest in Allakos Inc. (NASDAQ:ALLK) Increases By 9.1%

Allakos Inc. (NASDAQ:ALLK  Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development FocusRelated Stocks: ALLK...

Allakos says restructuring extends cash runway into mid-2026

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Allakos reports Q4 EPS (71c), consensus (47c)

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company ) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...

Commit To Buy Allakos At $1, Earn 17.9% Annualized Using Options

Investors eyeing a purchase of Allakos Inc (ALLK) shares, but cautious about paying the going market price of 1.48/share, might benefit from considering selling puts among the alternative...

Allakos Inc. (NASDAQ:ALLK) Given Average Rating of "Hold" by Analysts

Shares of Allakos Inc. (NASDAQ:ALLK  Get Free Report) have earned an average rating of Hold from the seven analysts that are currently covering the company, MarketBeat Ratings...

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Current Price	$0.3291
Prev Close	$0.3293
Open	$0.3283
Dividend Yield	0.00%
50-Day Moving Average	$0.3035
Beta	1.77
Avg. Volume	2.08M
PE Ratio	-0.41

52-Week High	$1.56
52-Week Low	$0.2157
Market Capitalization	$29.74M
EPS (Annual)	-$1.30
Price to Book	0.54
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALLK
Allakos Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALLK News

ALLK Allakos Inc